Skorpios Trust Sells 1,937,500 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) major shareholder Skorpios Trust sold 1,937,500 shares of the firm’s stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the transaction, the insider now directly owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Stoke Therapeutics Price Performance

NASDAQ STOK traded down $0.48 on Monday, hitting $13.27. 600,519 shares of the company’s stock were exchanged, compared to its average volume of 808,356. The firm’s 50-day moving average price is $14.50 and its two-hundred day moving average price is $13.21. The firm has a market cap of $691.65 million, a price-to-earnings ratio of -5.51 and a beta of 0.96. Stoke Therapeutics, Inc. has a fifty-two week low of $3.35 and a fifty-two week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.11. The business had revenue of $4.83 million for the quarter, compared to analyst estimates of $3.33 million. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%. On average, research analysts predict that Stoke Therapeutics, Inc. will post -2.18 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Stoke Therapeutics

Several institutional investors have recently modified their holdings of the company. Lynx1 Capital Management LP lifted its stake in Stoke Therapeutics by 40.3% in the 2nd quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock valued at $70,052,000 after buying an additional 1,488,371 shares in the last quarter. Redmile Group LLC lifted its stake in Stoke Therapeutics by 93.2% in the 1st quarter. Redmile Group LLC now owns 5,073,049 shares of the company’s stock valued at $68,486,000 after buying an additional 2,447,543 shares in the last quarter. Baker BROS. Advisors LP lifted its stake in Stoke Therapeutics by 65.9% in the 1st quarter. Baker BROS. Advisors LP now owns 3,368,443 shares of the company’s stock valued at $45,474,000 after buying an additional 1,338,309 shares in the last quarter. Vanguard Group Inc. lifted its stake in Stoke Therapeutics by 4.1% in the 1st quarter. Vanguard Group Inc. now owns 1,715,554 shares of the company’s stock valued at $23,160,000 after buying an additional 67,052 shares in the last quarter. Finally, Assenagon Asset Management S.A. purchased a new stake in Stoke Therapeutics in the 2nd quarter valued at approximately $19,835,000.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Wedbush restated an “outperform” rating and issued a $17.00 price target on shares of Stoke Therapeutics in a research report on Thursday, July 11th. HC Wainwright restated a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, September 11th. Finally, Needham & Company LLC restated a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $21.40.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.